At last month's JPMorgan Healthcare ... Revenues from the Sanofi collaboration were $1.2 billion, of which $1 billion related to our share of collaboration profits. Regeneron's share of profits ...

Sanofi said on Thursday it would ... 2025 Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake ...

It was another strong quarter for Dupixent – a drug for inflammatory diseases that it develops with Sanofi ... Baron Health Care Fund stated the following regarding Regeneron Pharmaceuticals ...

Sanofi and Regeneron’s checkpoint ... much to be done to improve therapy. According to Regeneron, there is no approved standard of care after first-line chemotherapy in advanced cervical cancer.

The oncology sector covers the entire cancer care process ... an eczema treatment whose rights Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares with Sanofi. Eylea, which Regeneron ...

Meanwhile, Sanofi and Regeneron are also running another trial of Kevzara in hospitalised patients with severe and critical COVID-19 using a different dosing regimen.

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...